ewing's sarcoma cells
Recently Published Documents


TOTAL DOCUMENTS

83
(FIVE YEARS 1)

H-INDEX

24
(FIVE YEARS 0)

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Christian Marx ◽  
Marc U. Schaarschmidt ◽  
Joanna Kirkpatrick ◽  
Lisa Marx-Blümel ◽  
Melisa Halilovic ◽  
...  

Abstract Introduction Ewing's sarcoma is an aggressive childhood malignancy whose outcome has not substantially improved over the last two decades. In this study, combination treatments of the HSP90 inhibitor AUY922 with either the ATR inhibitor VE821 or the ATM inhibitor KU55933 were investigated for their effectiveness in Ewing's sarcoma cells. Methods Effects were determined in p53 wild-type and p53 null Ewing's sarcoma cell lines by flow cytometric analyses of cell death, mitochondrial depolarization and cell-cycle distribution as well as fluorescence and transmission electron microscopy. They were molecularly characterized by gene and protein expression profiling, and by quantitative whole proteome analysis. Results AUY922 alone induced DNA damage, apoptosis and ER stress, while reducing the abundance of DNA repair proteins. The combination of AUY922 with VE821 led to strong apoptosis induction independent of the cellular p53 status, yet based on different molecular mechanisms. p53 wild-type cells activated pro-apoptotic gene transcription and underwent mitochondria-mediated apoptosis, while p53 null cells accumulated higher levels of DNA damage, ER stress and autophagy, eventually leading to apoptosis. Impaired PI3K/AKT/mTOR signaling further contributed to the antineoplastic combination effects of AUY922 and VE821. In contrast, the combination of AUY922 with KU55933 did not produce a cooperative effect. Conclusion Our study reveals that HSP90 and ATR inhibitor combination treatment may be an effective therapeutic approach for Ewing's sarcoma irrespective of the p53 status.


2020 ◽  
Vol 32 (11) ◽  
pp. 115101
Author(s):  
Veronica da Silva Ferreira ◽  
Mateus Ferreira Conz Eugenio ◽  
Elaine Del Nery dos Santos ◽  
Wanderley de Souza ◽  
Celso Sant’Anna

2020 ◽  
Author(s):  
Christian Marx ◽  
Marc U. Schaarschmidt ◽  
Joanna Kirkpatrick ◽  
Lisa Marx-Blümel ◽  
Doerte Hoelzer ◽  
...  

Abstract Introduction: Ewing's sarcoma is an aggressive childhood malignancy whose outcome has not substantially improved over the last two decades. In this study, combination treatments of the HSP90 inhibitor AUY922 with either the ATR inhibitor VE821 or the ATM inhibitor KU55933 were investigated for their effectiveness in Ewing's sarcoma cells.Methods: Effects were determined in p53 wild-type and p53 null Ewing's sarcoma cell lines by flow cytometric analyses of cell death, mitochondrial depolarization and cell-cycle distribution. They were molecularly characterized by gene and protein expression profiling, and by quantitative whole proteome analysis.Results: AUY922 alone induced DNA damage, apoptosis and ER stress, while reducing the abundance of DNA repair proteins. The combination of AUY922 with VE821 led to strong apoptosis induction independent of the cellular p53 status, yet based on different molecular mechanisms. p53 wild-type cells activated pro-apoptotic gene transcription and underwent mitochondria-mediated apoptosis. p53 null cells, however, accumulated higher levels of DNA damage, ER stress and autophagy, eventually leading to apoptosis. Impaired PI3K/AKT/mTOR signaling further contributed to the antineoplastic combination effects of AUY922 and VE821 in p53 null cells. In contrast, the combination of AUY922 with KU55933 did not produce a cooperative effect.Conclusion: Our study reveals that HSP90 and ATR inhibitor combination treatment may be an effective therapeutic approach for Ewing's sarcoma irrespective of the p53 status.


2020 ◽  
Vol 146 (11) ◽  
pp. 2871-2883
Author(s):  
Sophie L. Kerschner-Morales ◽  
Marie Kühne ◽  
Sabine Becker ◽  
James F. Beck ◽  
Jürgen Sonnemann

Abstract Purpose Polo-like kinase 4 (PLK4) inhibitors, such as CFI-400945 and centrinone, are emerging as promising antineoplastic agents. However, their effectiveness against Ewing’s sarcoma, a highly aggressive childhood cancer, remains to be established. Methods CFI-400945 and centrinone were tested in three Ewing’s sarcoma cell lines with different TP53 status. Effects were assessed by flow-cytometric analyses of cell death, dissipation of the mitochondrial transmembrane potential and cell cycle distribution, by cell viability assay as well as by caspase 3/7 activity measurement, by immunoblotting and by immunofluorescence microscopy. Results CFI-400945 and centrinone elicited cell death in p53 wild-type and mutant Ewing’s sarcoma cells. Both agents induced mitochondrial membrane depolarisation, caspase 3/7 activation, PARP1 cleavage and DNA fragmentation, indicating an apoptotic form of cell death. In addition, the PLK4 inhibitors induced a G2/M cell cycle arrest, particularly when cell killing was attenuated by the pan-caspase inhibitor z-VAD-fmk. Moreover, CFI-400945 treatment produced polyploidy. Conclusion Our findings show that PLK4 inhibitors were effective against Ewing’s sarcoma cells in vitro and thus provide a rationale for their evaluation in vivo.


2019 ◽  
Vol 20 (23) ◽  
pp. 6073 ◽  
Author(s):  
Alexander Romswinkel ◽  
Manfred Infanger ◽  
Carlo Dietz ◽  
Florian Strube ◽  
Armin Kraus

We studied the behavior of Ewing’s Sarcoma cells of the line A673 under simulated microgravity (s-µg). These cells express two prominent markers—the oncogene EWS/FLI1 and the chemokine receptor CXCR4, which is used as a target of treatment in several types of cancer. The cells were exposed to s-µg in a random-positioning machine (RPM) for 24 h in the absence and presence of the CXCR4 inhibitor AMD3100. Then, their morphology and cytoskeleton were examined. The expression of selected mutually interacting genes was measured by qRT-PCR and protein accumulation was determined by western blotting. After 24 h incubation on the RPM, a splitting of the A673 cell population in adherent and spheroid cells was observed. Compared to 1 g control cells, EWS/FLI1 was significantly upregulated in the adherent cells and in the spheroids, while CXCR4 and CD44 expression were significantly enhanced in spheroids only. Transcription of CAV-1 was upregulated and DKK2 and VEGF-A were down-regulated in both, adherent in spheroid cells, respectively. Regarding, protein accumulation EWS/FLI1 was enhanced in adherent cells only, but CD44 decreased in spheroids and adherent cells. Inhibition of CXCR4 did not change spheroid count, or structure. Under s-µg, the tumor marker EWS/FLI1 is intensified, while targeting CXCR4, which influences adhesion proteins, did not affect spheroid formation.


2018 ◽  
Vol 18 (1) ◽  
Author(s):  
Masanori Kawano ◽  
Kazuhiro Tanaka ◽  
Ichiro Itonaga ◽  
Tatsuya Iwasaki ◽  
Hiroshi Tsumura

2017 ◽  
Vol 51 (6) ◽  
pp. 1842-1850 ◽  
Author(s):  
Masanori Kawano ◽  
Kazuhiro Tanaka ◽  
Ichiro Itonaga ◽  
Tatsuya Iwasaki ◽  
Hiroshi Tsumura

2017 ◽  
Vol 51 (6) ◽  
pp. 1785-1792 ◽  
Author(s):  
Conglin Ye ◽  
Xiaolong Yu ◽  
Jin Zeng ◽  
Min Dai ◽  
Bin Zhang

Sign in / Sign up

Export Citation Format

Share Document